Related Experiment Video

Updated: May 19, 2026

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a

Yusuf Yilmaz1,2, Ming-Lung Yu1,3, Khalid Alswat1,4

  • 1The Global Liver and Global NASH/MASH Councils, Washington, District of Columbia, USA.

Journal of Viral Hepatitis
|May 18, 2026
PubMed

Insights

Significant fatigue affects nearly 20% of patients with chronic viral hepatitis, leading to reduced quality of life and work productivity. Early assessment and management of fatigue in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) are crucial.

Area of Science:

  • Hepatology
  • Patient-Reported Outcomes Research
  • Clinical Psychology

Background:

  • Fatigue is a common symptom in chronic viral hepatitis, potentially impacting patients' quality of life.
  • Patient-reported outcomes (PROs) are crucial for understanding the patient experience in chronic liver diseases.
  • Chronic hepatitis B (CHB) and chronic hepatitis C (CHC) represent significant global health challenges.

Purpose of the Study:

  • To evaluate the association between fatigue and various PROs in patients with CHB and CHC.
  • To identify factors associated with fatigue in these patient populations.
  • To quantify the impact of fatigue on health-related quality of life and work productivity.

Main Methods:

  • Cross-sectional study of 2888 patients with CHB or CHC from the Global Liver Registry.
  • PRO instruments used included FACIT-F, CLDQ (for CHB), CLDQ-HCV (for CHC), and WPAI:SHP.
  • Fatigue was defined using the FACIT-F Fatigue Scale score < 30.

Main Results:

  • 17% of CHB patients and 28% of CHC patients reported significant fatigue.
  • Fatigue in CHB was linked to younger age, female sex, obesity, anxiety, and depression, with significant PRO impairment.
  • Fatigue in CHC was associated with female sex, obesity, type 2 diabetes, anxiety, and depression, showing substantial PRO and work productivity impairment.

Conclusions:

  • Nearly one in five patients with chronic viral hepatitis experience significant fatigue.
  • Fatigue is strongly associated with decreased health-related quality of life and impaired work productivity in CHB and CHC patients.
  • Routine screening for and management of fatigue should be integrated into the care of patients with CHB and CHC.

Keywords:
anxietydepressionfemaleobesitywork impairment

More Related Videos

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Fatigue01:21

Fatigue

Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...